Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
Portfolio Pulse from The Dales Report
Awakn Life Sciences Corp. (OTC:AWKNF) has submitted a Clinical Trial Application (CTA) for a phase III clinical trial for its leading program, AWKN-P001, designed for the treatment of Severe Alcohol Use Disorder (SAUD). The trial will be conducted at ten UK National Health Service (NHS) sites and will involve 280 participants. The company expects to receive feedback on the CTA in the coming months and aims to commence treatment in late Q4 2023 or early Q1 2024.
September 06, 2023 | 9:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Awakn Life Sciences has submitted a CTA for a phase III clinical trial for AWKN-P001, a treatment for SAUD. The trial is expected to commence in late Q4 2023 or early Q1 2024.
The submission of the CTA for the phase III clinical trial is a significant step for Awakn Life Sciences. If approved, it could potentially lead to the commercialization of AWKN-P001, which would be a significant revenue driver for the company. This news is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100